Nomogram based on radiomics analysis of ultrasound images can improve preoperative BRAF mutation diagnosis for papillary thyroid microcarcinoma
Jiajia Tang1,2, Shitao Jiang3, Jiaojiao Ma2, Xuehua Xi2, Huilin Li1,2, Liangkai Wang2,4 and Bo Zhang1,5

The US radiomics nomogram displayed better performance than the conventional US model in predicting BRAF mutation in patients with PTMC.

Front. Endocrinol. 13:915135.

Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
Wenjin Yin1, YaohuiWang1, ZipingWu1, Yumei Ye1, Liheng Zhou1, Shuguang Xu1, Yanping Lin1, Yueyao Du1, Tingting Yan1, Fan Yang1, Jie Zhang1, Qiang Liu2, and Jinsong Lu1

The addition of pyrotinib to trastuzumab plus chemotherapy is an efficacious and safe regimen for patients with HER2-positive locally advanced breast cancer in the neoadjuvant setting. The randomized controlled clinical trial is warranted to validate our results.

Clin Cancer Res. 2022 Sep 1;28(17):3677-3685. 

Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis
Yu Liu # 1 2 3, Bo Zhou # 4, Wentao Tang # 1 2 3, Donghao Xu # 1 2, Zhiping Yan 4, Li Ren 1 2 3, Dexiang Zhu 1 2 3, Guodong He 1 2 3, Ye Wei 1 2 3, Wenju Chang 5 6 7, Jianmin Xu 8 9 10

In patients who became resectable after conversion therapy, preoperative DEB-TACE might be a safe option to achieve longer RFS.

Eur Radiol. 2022 Sep 6. 

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
Sai-Hong Ignatius Ou 1, Makoto Nishio 2, Myung-Ju Ahn 3, Tony Mok 4, Fabrice Barlesi 5, Caicun Zhou 6, Enriqueta Felip 7, Filippo de Marinis 8, Sang-We Kim 9, Maurice Pérol 10, Geoffrey Liu 11, Maria Rita Migliorino 12, Dong-Wan Kim 13, Silvia Novello 14,

In ALK in Lung Cancer Trial of brigAtinib-2,brigatinib was found to have a limited activity in patients with ALKþ NSCLC post-ceritinib or post-alectinib therapy.mPFS was longer with brigatinib in patients without baseline detectable plasma ALK fusion.

J Thorac Oncol. 2022 Dec;17(12):1404-1414. 

Primary intraosseous Rosai–Dorfman disease: An analysis of clinicopathologic characteristics, molecular genetics, and prognostic features
Xin Weng, 1 , † Yajie Yang, 1 , † Meng Zhang, 1 Chang Cai, 1 Yanhua Sun, 1 Xikang Wu, 1 Rongrong Zhang, 1 Huihui Gui, 1 Wei Li, 2 Qizhong Xu, 3 and Xia Liu1

Primary intraosseous RDD is an extremely rare disease. The diagnosis of RDD may be quite challenging because of its non-specific clinical presentation and imaging. Immunohistochemistry showed that large histiocytes were positive for OCT2 in addition to S100 and CD68, which may be helpful for differential diagnosis. Molecular detection showed that RDD may be related to the MAPK pathway, though these results are also ultimately not specific. The pathogenesis of RDD is yet to be elucidated, but recent studies suggest possible clonality of hyperproliferative histiocytes.

Front Oncol. 2022; 12: 950114.

PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma
Jianhua Liu1,2 · Hao Chen3 · Guibin Qiao4 · Jia‑Tao Zhang5 · Shuaitong Zhang6,7 · Changbin Zhu8 · Yu Chen9 · Jiming Tang4 · Weiwei Li8 · Siyun Wang10 · Hongxia Tian5 · Zhihong Chen5 · Dong Ma2 · Jie Tian6,7 · Yi‑Long Wu5,1

PLEK2 and IFI6 was discovered of first time to identify a distinct ESCC subpopulation cannot be benefited from neoadjuvant immunotherapy and present a poor survival, which putatively associated with mesenchymal and immunesuppressive microenvironment.
 

Cancer Immunol Immunother. 2022 Sep 19.